Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have received an average recommendation of "Buy" from the six ratings firms that are currently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $8.20.

GANX has been the topic of a number of recent research reports. Chardan Capital reissued a "buy" rating and set a $6.00 target price on shares of Gain Therapeutics in a research report on Friday, March 28th. HC Wainwright reissued a "buy" rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Monday, March 17th. Finally, Scotiabank assumed coverage on Gain Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $12.00 target price for the company.

Gain Therapeutics Trading Up 2.4 %

Shares of GANX stock traded up $0.05 during trading hours on Friday, reaching $2.10. 223,078 shares of the stock traded hands, compared to its average volume of 299,040. The business has a fifty day moving average price of $1.93 and a 200 day moving average price of $2.07. Gain Therapeutics has a 1-year low of $0.89 and a 1-year high of $3.19. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $60.37 million, a PE ratio of -1.92 and a beta of 0.18.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.07. On average, equities research analysts forecast that Gain Therapeutics will post -1 EPS for the current year.

Hedge Funds Weigh In On Gain Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Sprott Inc. bought a new position in shares of Gain Therapeutics during the 4th quarter worth approximately $30,000. Benedict Financial Advisors Inc. acquired a new stake in Gain Therapeutics during the 4th quarter valued at $35,000. Bridgeway Capital Management LLC bought a new position in Gain Therapeutics during the fourth quarter worth $65,000. Northern Trust Corp increased its holdings in shares of Gain Therapeutics by 88.2% in the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after purchasing an additional 39,642 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Gain Therapeutics in the fourth quarter valued at about $198,000. 11.97% of the stock is owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.